The Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND trial is a multicentre, open-label, single and multiple dose-escalation and pharmacokinetic study of Cu(II)ATSM to determine the recommended phase 2 dose.
The Principal Investigator is Professor Matthew Kiernan, Sydney Neurology. Recruitment is expected to commence in the next few months for individuals who meet specific inclusion criteria. For detailed information including recruitment and exclusion criteria see https://clinicaltrials.gov/ct2/show/NCT02870634. For more general information for people considering participating in research see here.